← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vascular Biosciences
San Diego, CA
$6,467,405
Total funding
5
Grants
Funding over time
peak $1.3M · FY2008–22$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,467,405 · 5
By mechanism
R42$4,932,143 · 2
N01$1,149,127 · 1
R41$386,135 · 2
Investigators at Vascular Biosciences
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$1,291,298
R42 · FY2021 · HL
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension$1,255,432
R42 · FY2018 · HL
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$1,006,870
R42 · FY2022 · HL
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension$746,137
R42 · FY2019 · HL
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS AND THERAPEUTIC ADVANCES (VITA): CAR PEPTIDE THERAPEUTIC ADJUVANT FOR PAH TARGETED THERAPY$401,635
N01 · FY2015 · HL
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS AND THERAPEUTIC ADVANCES (VITA): CAR PEPTIDE THERAPEUTIC ADJUVANT FOR PAH TARGETED THERAPY$385,534
N01 · FY2016 · HL
IGF::OT::IGF VASCULAR INTERVENTIONS/INNOVATIONS AND THERAPEUTIC ADVANCES (VITA): CAR PEPTIDE THERAPEUTIC ADJUVANT FOR PAH TARGETED THERAPY$361,958
N01 · FY2014 · HL
Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH$330,004
R42 · FY2020 · HL
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension$302,402
R42 · FY2017 · HL
Injury-targeted decorin for systemic anti-fibrotic treatment$220,390
R41 · FY2011 · GM
Targeting Pulmonary Hypertension with R-Ras$165,745
R41 · FY2008 · HL